1100748-84-2

Basic information

• Product Name: 1-Amino-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester
• Synonyms: 1-Amino-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester;1-AMino-7-Boc-7-azaspiro[...;1-AMino-7-Boc-7-azaspiro[3.5]nonane;tert-butyl 1-aMino-7-azaspiro[3.5]nonane-7-carboxylate
• CAS NO: 1100748-84-2
• Molecular Formula: C₁₃H₂₄N₂O₂
• Molecular Weight: 240
• Mol File: 1100748-84-2.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 337℃
• Flash Point: 157℃
• Appearance: /
• Density: 1.08
• PKA: 10?+-.0.20(Predicted)
• CAS DataBase Reference: 1-Amino-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Amino-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester(1100748-84-2)
• EPA Substance Registry System: 1-Amino-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester(1100748-84-2)

Safety Data

• Hazardous Substances Data: 1100748-84-2(Hazardous Substances Data)

Usage

Uses

1-Amino-7-azaspiro[3.5]nonane-7-carboxylic Acid tert-Butyl Ester is a reagent used in the synthesis of series of spiro scaffolds for drug discovery.

Upstream product

• 1100748-83-1 tert-butyl 1-(benzylamino)-7-azaspiro[3.5 ]nonane-7-carboxylate 

Downstream Products

• 1100748-78-4 1-amino-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester hydrochloride 
• 1100748-83-1 tert-butyl 1-(benzylamino)-7-azaspiro[3.5 ]nonane-7-carboxylate 

Relevant articles and documents

ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES

The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity particularly involved in the development and maintenance of persistent or chronic pain, and / or neurological disorders. These novel compounds are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which these ion channels are involved. The invention is also directed towards pharmaceutical formulations comprising these compounds and the uses of these compounds.